Assessing the Utility of the Montreal Cognitive Assessment in Screening for Cognitive Impairment in Patients With Systemic Lupus Erythematosus.
Oshrat E Tayer-ShifmanKimberley YuenRobin GreenMahta KakvanPatricia P KatzKathleen S BinghamJuan Pablo Diaz-MartinezLesley RuttanJoan E WitherMaria Carmela TartagliaJiandong SuDennisse BonillaMay Yee ChoiSimone AppenzellerMichelle BarracloughDorcas E BeatonZahi ToumaPublished in: Arthritis care & research (2022)
The MoCA does not have adequate concurrent criterion validity to accurately identify CI in patients with SLE. The low specificity of the MoCA may lead to overdiagnosis and concern among patients. Adding the MoCA to the ANAM does not substantially improve the accuracy of the ANAM. These results do not support using the MoCA as a screening tool for CI in patients with SLE.